文献速递消化系统肿瘤

转移性结直肠癌多线治疗生存评估:FIRE-3试验(AIO KRK0306)分析

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
PubMed 文献 · Eur J Cancer · 2017-08-23

该分析基于FIRE-3试验,探索序贯多线治疗对生存动力学的影响,按时间间隔及Cox模型分析FOLFIRI联合西妥昔单抗或贝伐珠单抗的总生存。Cox模型提示两组风险比有非比例趋势(KRAS-ITT P=0.12,all-RAS野生型 P=0.09),估计变点位于随机化后22.6个月(第687天);变点前HR与1无显著差异,变点后西妥昔单抗组生存动力学明显更优(KRAS-ITT:P=0.0018,HR 0.60 [95%CI 0.44-0.83];RAS:P=0.0006,HR 0.51 [95%CI 0.35-0.75])。结论认为仅生存超过22.6个月的患者从西妥昔单抗组的优效中获益。

要点

  • Cox模型提示两组风险比呈非比例趋势(KRAS-ITT P=0.12,all-RAS野生型 P=0.09)。
  • 估计变点位于随机化后22.6个月(第687天)。
  • 变点后西妥昔单抗组生存更优(KRAS-ITT HR 0.60,RAS HR 0.51)。

核心结论

  • 总生存差异在随机化后约22.6个月显现并利于西妥昔单抗组,提示仅生存超过22.6个月的患者从西妥昔单抗组的优效中获益。
  • 生存曲线分离时仅少数患者在接受短程活跃全身治疗,提示早期治疗效应决定后期生存曲线动力学。

研究设计与样本

  • 基于FIRE-3试验的分析,按FOLFIRI联合西妥昔单抗或贝伐珠单抗分层进行总生存分析。
  • 采用时间间隔分析及Cox模型评估风险比随时间的变化。

主要发现

  • 接受全身治疗的患者比例及治疗时间随治疗线数和时间明显下降。
  • Cox模型提示两组风险比呈非比例趋势(KRAS-ITT P=0.12,all-RAS野生型 P=0.09)。
  • 估计变点为随机化后22.6个月(第687天)。
  • 变点前两组HR与1无显著差异。
  • 变点后西妥昔单抗组生存动力学明显更优(KRAS-ITT:P=0.0018,HR 0.60 [95%CI 0.44-0.83];RAS:P=0.0006,HR 0.51 [95%CI 0.35-0.75])。

关键数值与推荐

  • KRAS-ITT人群变点后HR 0.60(95%CI 0.44-0.83),P=0.0018。
  • all-RAS野生型人群变点后HR 0.51(95%CI 0.35-0.75),P=0.0006。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in FIRE-3 were investigated in the context of time and exposure to applied treatment. PATIENTS AND METHODS: OS analyses (stratified by treatment with FOLFIRI plus either cetuximab or bevacizumab) were performed according to time intervals as well as using a Cox model to define changes of hazard ratio (HR) over time. RESULTS: The fraction of patients with systemic treatment and time on treatment markedly decreases over treatment lines and time. OS evaluation by a Cox model indicated a trend towards a non-proportional hazard between treatment arms (P = 0.12/P = 0.09 for KRAS-intention-to-treat (ITT)/all-RAS wild-type populations, respectively). To improve the fit of the model, a change-point (point of curve separation) was estimated at 22.6 months (day 687) after randomisation. The HR between the two arms before 22.6 months was not significantly different from one. However, markedly different survival kinetics in favour of the cetuximab arm were apparent after the change-point (KRAS-ITT: P = 0.0018; HR, 0.60 [95% confidence interval [CI], 0.44-0.83] and RAS: P = 0.0006; HR, 0.51 [95% CI, 0.35-0.75]). CONCLUSION: The differences in OS favouring the cetuximab arm become apparent about 22.6 months after randomisation, indicating that only those patients who survive 22.6 months after randomisation benefit from the superiority of the cetuximab arm. When OS curves separate, only few patients receive active systemic treatment in short courses, suggesting that earlier treatment effects are responsible for later kinetics of survival curves.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Modest DP, Ricard I, Stintzing S, et al. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). Eur J Cancer. 2017. PMID: 28843184. doi:10.1016/j.ejca.2017.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。